Prostate cancer (PCa), one of the current world’s major health concerns has the highest incidence of any type of cancer. It is the 2nd most common type of cancer and the 5th most frequent cause of cancer-related death in men worldwide. PCa develops after the age of fifty in men. Unfortunately, many patients do not have indications, they don’t take treatment & 2/3rd of cases of PCa grow slowly. High-risk tumour predicts prostate-specific antigen (PSA) levels ≥20ng/mL, stage T3-T4 disease, or Gleason scores ≥7. These characteristics are represented by 20-30% of PCa patients.
Hormone therapy & external beam radiotherapy alone are found to be effective and acceptable methods in locally advanced PCa. Both methods have certain side effects.
• Frequent urge to urinate, dysuria, nocturia & genitourinary irritation
• Enhanced desire to defecate & rectal mucus passage or bleeding
• Raise in risk of development of secondary malignancies in 10-15 years
• Palpitation, hot flashes, headache, tiredness, fatigue & gynecomastia
• Libido loss & erectile dysfunction
• Weight gain or loss of muscle mass
• Mood swings, depression & impaired vision
• Cardiac attack & stroke
Treatment of high-risk PCa is not easy due to its poorer interpretation. One of the chief therapies for enlarged prostrate (>60 mL) is a combination of radiation therapy and hormone therapy.
Neoadjuvant therapy includes hormone therapy, simultaneously adjuvant therapy of percutaneous radiation is provided. Androgen receptor blockers like bicalutamide or gonadotropin-releasing.
hormone & agonists like goserelin or antagonists like degarelix are also prescribed. Hormone therapy sterilizes occult metastases & radiation kills tumor cells irrespective of hormone sensitivity in cumulative cooperation. This unique combination offers 1. Increasing dose allowance with low toxicity offers prostatic volume debulking 2. Enhanced radiosensitivity due to tumor hypoxia reduction 3. Decrease cell repopulation during radiation therapy because of cell cycle slowing 4. Immunomodulation-induced apoptosis and direct effect on tumour cells 5. Supra-additive effect The advantages of combination therapy include better biochemical regulation, up to 50% drop in prostate volume, cancer-specific & relapse-free survival & overall improved survival benefits & lowered cancer reappearance and positive influence on total mortality & disease-specific mortality rate.
Combination therapy of radiation & hormone therapy in PCa requires more focused clinical trials in order to make it more suitable & usable. Simultaneously detailed patient investigation records including the onset of PCa, evolution, statin intake, diet habits & patterns, daily lifestyle, weight & body mass index, smoking and PCa screening type needs to be maintained. A combination of radiation & hormone therapy can be used as a remedy choice for moderate to high-risk localized PCa patients but the benefit is still not very clear in low-risk PCa patients. While using the combination therapy side effects should be managed efficiently and promptly.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation